ChemicalBook > CAS DataBase List > "(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "

"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "

Product Name
"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "
CAS No.
953778-63-7
Chemical Name
"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "
Synonyms
TTA-A2;TTA-A2, 10 mM in DMSO;(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamid;Benzeneacetamide, 4-cyclopropyl-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]ethyl]-;2-(4-cyclopropylphenyl)-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide;"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide ";Pregnane X receptor,TTA-A2,neurological diseases,T-type calcium channel,Inhibitor,Ca2+ channels,Ca channels,Electrocorticogram,TTAA2,sleep disorders,TTA-A-2,inhibit,TTA A2,Epilepsy,Calcium Channel
CBNumber
CB43120851
Molecular Formula
C20H21F3N2O2
Formula Weight
378.39
MOL File
953778-63-7.mol
More
Less

"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide " Property

Boiling point:
538.5±50.0 °C(Predicted)
Density 
1.258±0.06 g/cm3(Predicted)
solubility 
DMSO: Soluble: =10 mg/ml
Ethanol: Soluble: =10 mg/ml
form 
Solid
pka
14.29±0.46(Predicted)
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P330Rinse mouth.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0093037
Product name
TTA-A2
Purity
≥99.0%
Packaging
1mg
Price
$250
Updated
2021/12/16
Crysdot
Product number
CD11004405
Product name
(R)-2-(4-Cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
Purity
97%
Packaging
100mg
Price
$980
Updated
2021/12/16
More
Less

"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide " Chemical Properties,Usage,Production

Uses

TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy[1][2].

in vivo

TTA-A2 (oral gavage; 3 mg/kg; single dose) produces significant changes in sleep architecture in rats. A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep. Additionally, these effects persists for up to 4 h post-dose in rats[1].TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[2].

Animal Model:Wild-type and double Cav3.1/Cav3.3 knockout C57BL6/Sv129 background mices[2]
Dosage:10mg/kg
Administration:Oral gavage; 10mg/kg; once daily; 5 days
Result:Blocked active wake and promotes slow-wave sleep in wild-type mice but not mutant mice.

IC 50

T-type calcium channel

References

[1] Thomas S Reger, et al.Pyridyl amides as potent inhibitors of T-type DOI:10.1016/j.bmcl.2011.01.089

[2] Richard L Kraus, et al.In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther. 2010 Nov;335(2):409-17. DOI:10.1124/jpet.110.171058
[3] NEEMA KUMARI  Subha N R  Anamika Bhargava. T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line[J]. Life sciences, 2020, 260: Article 118291. DOI: 10.1016/j.lfs.2020.118291

[4] VICTOR N UEBELE. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.[J]. The Journal of clinical investigation, 2009: 1659-1667. DOI: 10.1172/jci36954

[5] JASON M. USLANER . T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats[J]. Neuropharmacology, 2012, 62 3: Pages 1413-1421. DOI: 10.1016/j.neuropharm.2010.11.015

[6] MARC CHEVALIER. T-type calcium channels are involved in hypoxic pulmonary hypertension.[J]. Cardiovascular Research, 2014, 103 4: 597-606. DOI: 10.1093/cvr/cvu166

"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide " Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

"(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide " Suppliers

China 46 United States 3 Global 49
SHANGHAI FORTUNE CHEMICAL TECHNOLOGY CO., LTD
Tel
13816107857
Fax
qq: 276312098
Email
sales@fortunechem-sh.com
Country
China
ProdList
984
Advantage
58
Bide Pharmatech Ltd.
Tel
400-400-164-7117 18317119277
Fax
+86-21-61629029
Email
product02@bidepharm.com
Country
China
ProdList
39999
Advantage
60
HangZhou YuHao Chemical Technology Co., Ltd.
Tel
0571-82693216
Fax
0571-82880190
Email
info@yuhaochemical.com
Country
China
ProdList
2028
Advantage
58
Cool Pharm, Ltd
Tel
021-60455363 18019463053
Fax
50966098
Email
sales@coolpharm.com
Country
China
ProdList
5397
Advantage
58
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696，15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4827
Advantage
55
AN PharmaTech Co Ltd
Tel
86(21)68097365
Fax
86(21)33321566
Email
sales@anpharma.net
Country
China
ProdList
4891
Advantage
55
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
86249
Advantage
60
Shanghai Chaolan Chemical Technology Center
Tel
021-QQ：65489617 15618227136
Fax
21-5161 9052
Email
Sales@ATKchemical.com
Country
China
ProdList
9550
Advantage
58
Amadis Chemical Company Limited
Tel
571-89925085
Fax
0086-571-89925065
Email
sales@amadischem.com
Country
China
ProdList
131957
Advantage
58
Heze Development Zone chuangli Chemical Co., Ltd.
Tel
0530-+86-530-529 6766，+86-15666160102 15666160102
Fax
0530-529 6766
Email
info@chuangli-chem.com
Country
China
ProdList
852
Advantage
55

953778-63-7, "(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "Related Search:


  • "(R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide "
  • TTA-A2
  • (R)-2-(4-cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamid
  • 2-(4-cyclopropylphenyl)-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide
  • Benzeneacetamide, 4-cyclopropyl-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)-2-pyridinyl]ethyl]-
  • Pregnane X receptor,TTA-A2,neurological diseases,T-type calcium channel,Inhibitor,Ca2+ channels,Ca channels,Electrocorticogram,TTAA2,sleep disorders,TTA-A-2,inhibit,TTA A2,Epilepsy,Calcium Channel
  • TTA-A2, 10 mM in DMSO
  • 953778-63-7